Highlights from the international transporter consortium second workshop

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 5, 2012, Pages 553-556

  Zamek Gliszczynski, M J ^a   Hoffmaster, K A ^b   Tweedie, D J ^c   Giacomini, K M ^d   Hillgren, K M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT EXPORT PUMP; DRUG VEHICLE; MEMBRANE PROTEIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DECISION MAKING; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

COOPERATIVE BEHAVIOR; DECISION TREES; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; INTERNATIONALITY; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS;

EID: 84867780513     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.126     Document Type: Conference Paper

References (9)

1. Giacomini, K.M. et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
2. Damme, K., Nies, A.T., Schaeffeler, E. & Schwab, M. Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. Drug Metab. Rev. 43, 499-523 (2011).
3. Yonezawa, A. & Inui, K. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/ toxicodynamics and pharmacogenomics. Br. J. Pharmacol. 164, 1817-1825 (2011).
4. Ito, S. et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J. Pharmacol. Exp. Ther. 340, 393-403 (2012).
5. Keppler, D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb. Exp. Pharmacol. 201, 299-323 (2011).
6. Zamek-Gliszczynski, M.J., Hoffmaster, K.A., Nezasa, K., Tallman, M.N. & Brouwer, K.L. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci. 27, 447-486 (2006). (Pubitemid 43363339)
7. Stieger, B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb. Exp. Pharmacol. 201, 205-259 (2011).
8. Kalvass, J.C. & Pollack, G.M. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm. Res. 24, 265-276 (2007). (Pubitemid 46072186)
9. Zamek-Gliszczynski, M.J., Kalvass, J.C., Pollack, G.M. & Brouwer, K.L. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab. Dispos. 37, 386-390 (2009).